AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Advancements in Cancer Treatment and Corporate Milestones
This chapter explores recent breakthroughs in genetic medicine focused on treating Sickle Cell Disease, including Otomo Pharma's successful Series A funding of over $140 million. It also highlights the development of Jankis Tomek, a new bifunctional antibody for cancer therapy, and the company's strategic objectives in the oncology sector.